Research programme: respiratory disorder therapeutics - Five Prime Therapeutics/GlaxoSmithKline

Latest Information Update: 11 Nov 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Five Prime Therapeutics
Developer Five Prime Therapeutics; GlaxoSmithKline
Class Proteins
Mechanism of Action

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Asthma; Chronic obstructive pulmonary disease

Most Recent Events

06 Nov 2017 GlaxoSmithKline exercises option to exclusively license drug target from Five Prime Therapeutics for respiratory disorders
16 Jul 2016 No recent reports of development identified for research development in Asthma in USA
16 Jul 2016 No recent reports of development identified for research development in Chronic-obstructive-pulmonary-disease in USA

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.